Showing 1671-1680 of 2050 results for "".
- Abionyx Pharma Announces Its Strategy in Ophthalmologyhttps://modernod.com/news/abionyx-pharma-announces-its-strategy-in-ophthalmology/2481506/France-based Abionyx Pharma announced announced its strategy in ophthalmology and new positive preclinical results in two technological platforms: apotherapy and biovectorisation. "The acquisition of IRIS Pharma, one of the world leaders in contract research in ophthalmology,
- NIH: Eye Experts Weigh In on Artificial Tears in Midst of Infectious Outbreakhttps://modernod.com/news/nih-eye-experts-weigh-in-on-artificial-tears-in-midst-of-infectious-outbreak/2481452/The Centers for Disease Control and Prevention (CDC) is investigating how the virulent strain of P. aeruginosa ended up in EzriCare and Delsam Pharma artificial tears. According to an
- Aldeyra Therapeutics Announces Positive Topline Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-12-month-safety-clinical-trial-of-reproxalap-in-patients-with-dry-eye-disease/2481437/Aldeyra Therapeutics announced topline results from a 12-month, vehicle-controlled, multicenter, parallel-group safety clinical trial of reproxalap, an investigational new drug in dry eye disease patients. The primary endpoints of treatment-related serious adverse events in ocular safet
- Glaukos Submits NDA to FDA for iDose TRhttps://modernod.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.&
- Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Studyhttps://modernod.com/news/skye-bioscience-receives-positive-safety-review-of-sbi-100-ophthalmic-emulsion-after-second-cohort-of-phase-1-study/2481432/Skye Bioscience has received a positive recommendation following a prespecified data review by the safety review committee based on dosing of the second cohort of eight healthy participants of its phase 1 study of SBI-100 ophthalmic emulsion. The SRC has recommended that the trial conti
- CDC Expands Recall of OTC Artificial Tearshttps://modernod.com/news/cdc-expands-recall-of-otc-artificial-tears/2481430/After reports of additional infections, the Centers for Disease Control and Prevention (CDC) has expanded its recall of OTC eye drops to include Delsam Pharma’s Artificial Tears products. The call for immediate discontinuation comes a month after the agency recommended immediate discontinua
- Belkin Vision’s New Glaucoma Laser Technology Now Available in Germanyhttps://modernod.com/news/belkin-visions-new-glaucoma-laser-technology-now-available-in-germany/2481425/Belkin Vision announced that its Direct SLT Eagle device, an automated, non-contact glaucoma laser treatment, is being used to treat glaucoma patients at The University Eye Clinic in Bochum, Germany. “The Eagle by Belkin Vision will be transformative for many of the esti
- Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-positive-data-on-cls-ax-oasis-clinical-trial-and-use-of-scs-microinjector/2481423/Clearside Biomedical announced data from presentations delivered at the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting. “The promising durability data from our OASIS clinical trial continues to garner si
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Aura Biosciences Announces Positive Interim Phase 2 Data of Belzupacap Sarotalocan for Treatment of Early-Stage Choroidal Melanomahttps://modernod.com/news/aura-biosciences-announces-positive-interim-phase-2-data-of-belzupacap-sarotalocan-for-treatment-of-early-stage-choroidal-melanoma/2481414/Aura Biosciences announced the presentation of positive interim phase 2 safety and efficacy data of belzupacap sarotalocan (bel-sar) with an average of 9 months of follow up evaluating two key clinical endpoints: tumor control, and visual acuity preservation using the suprachoroidal (SC) rou